Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Drug shortage impact on cancer care and efforts to resolve the issue

2012 ASCO Annual Meeting

Published: 4 Jun 2012

Views: 3770

Rating:

Save

Dr Sandra Kweder - US Food and Drug Administration

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Sandra Kweder presents on the impact of recent drug shortages and ways to prevent shortages in the future.

Related Videos

Enhancing head and neck oncology: Key insights from the conference

Dr Anil D'Cruz - Apollo Hospitals, Mumbai, India

Enhancing head and neck oncology: Key insights from the conference ( Dr Anil D'Cruz - Apollo Hospitals, Mumbai, India )

Optimising multiple myeloma care in Latin America

Dr David Gómez-Almaguer - Autonomous University of Nuevo León, Monterrey, Mexico

Optimising multiple myeloma care in Latin America ( Dr David Gómez-Almaguer - Autonomous University of Nuevo León, Monterrey, Mexico )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

More from ecancer